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The transmembrane fusion (F) glycoprotein of measles virus is an important target antigen of human HLA
class I- and class IT-restricted cytotoxic T lymphocytes (CTL). Genetically engineered F proteins and nested sets
of synthetic peptides spanning the F protein were used to determine sequences of F recognized by a number of
F-specific CTL clones. Combined N- and C-terminal deletions of the respective peptides revealed that human
HLA class I and HLA class II-restricted CTL efficiently recognize nonapeptides or decapeptides representing
epitopes of F. Three distinct sequences recognized by three different HLA class II (DQwl, DR2, and
DR4/w53)-restricted CTL clones appear to cluster between amino acids 379 and 466 of F, thus defining an
important T-cell epitope area of F. Within this same region, a nonamer peptide ofF was found to be recognized
by an HLA-B27-restricted CTL clone, as expected on the basis of the structural homology between this peptide
and other known HLA-B27 binding peptides.
The two measles virus (MV) envelope glycoproteins, the
hemagglutinin (H) and the fusion (F) protein, are targets for
immune recognition by the immune system of an infected
human host (for reviews, see references 29, 34, and 38). The
generation of biologically active antibodies against the gly-
coproteins, i.e., hemagglutination- and fusion-inhibiting an-
tibodies and neutralizing antibodies induced by either infec-
tion with wild-type virus or vaccination with a live
attenuated vaccine, usually confers lifelong protective im-
munity against measles (4, 9, 12, 24, 25, 36, 46, 57, 59).
The failure of inactivated measles virus vaccines used thus
far to protect against measles upon reexposure to the virus
has been associated with an incomplete immune response
against the F protein (32, 33, 35, 37). This illustrates the
importance of the presentation of F in an immunogenic form
in future inactivated vaccines (33). The rationale and the
demands for the development of inactivated vaccines against
measles have recently been formulated by a World Health
Organization steering committee.
Identification of the immunogenic epitopes which are
recognized by B- and T-lymphocyte antigen receptors may
be of crucial importance for vaccine development. CD4+ T
lymphocytes which assist in the activation of B lymphocytes
and in their differentiation to antibody-producing cells rec-
ognize processed fragments of endocytosed protein antigen
presented by class II molecules of the major histocompati-
bility complex at the surface of antigen-presenting cells
(APC). CD8+ cytotoxic T lymphocytes (CTL) eliminate
virus-infected cells, since they express at their cell surface
processed fragments of endogenously synthesized viral pro-
teins which associate with class I major histocompatibility
complex molecules (for reviews, see references 2, 50, and
61).
For a number of virus infections, including MV infection,
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a major role in eliminating virus-infected cells has also been
attributed to CD4+ class II-restricted CTL (11, 17, 18, 26,
47, 60). However, we recently documented the predomi-
nance of CD8+ class I-restricted CTL in antiviral T-lympho-
cyte-mediated immunity (53).
In the present study, the epitope specificity and HLA
restriction of cloned F protein-specific human CTL were
documented. With ,B-galactosidase fusion proteins express-
ing different regions of F and a number of synthetic peptides,
nonameric and decameric sequences representing class I-
and class II-presentable epitopes clustering between amino
acids (aa) 379 and 466 could be identified.
MATERIALS AND METHODS
Antigen preparations. (i) MV. Plaque-purified MV (Ed-
monston B strain) was cultured on Vero cells, and 107 50%
tissue culture infective doses of MV per ml was routinely
used to infect human Epstein-Barr virus-transformed B-lym-
phoblastoid cell lines (B-LCL).
(ii) F. The F protein was purified from whole virus by
solubilizing purified MV with octyl 3-D-glucopyranoside (2%
[wtlvol] octyl glucoside; Sigma Chemical Co., St. Louis,
Mo.) and subjecting the resulting preparation to affinity
chromatography with F-specific monoclonal antibody 7-21
coupled to CNBr-activated Sepharose 4B as described pre-
viously (6).
(iii) F-13-galactosidase fusion proteins. 3-Galactosidase fu-
sion proteins containing both the 3-galactosidase protein and
combined C- and N-terminal fractions of F were expressed
in Escherichia coli AB1157 from pEX3 constructs as previ-
ously described (8). A set of different deletions was selected
on the basis of restriction and sequence analysis and sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting (immunoblotting) of the ex-
pressed proteins in E. coli. E. coli cells producing the
various 3-galactosidase fusion proteins were lysed with
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lysozyme (1 g/liter) for 40 min at 0°C and then treated for 5
min with 0.11% Triton X-100 in 25 mM Tris-HCl, (pH
8.0)-10 mM EDTA-50 mM glucose at 0°C. After centrifuga-
tion (20 min at 10,000 rpm [Sorvall SS-34 rotor]), the pellet
was resuspended in 0.1% Triton X-100-10 mM Tris-HCl-0.1
mM EDTA (pH 7.5). Triton X-100 was removed by centrif-
ugation of the proteins through a 20% sucrose cushion (10
min at 10,000 rpm [Sorvall SS-34 rotor]). The pellets were
resuspended in phosphate-buffered saline (PBS) solution
(pH 7.2) and sonicated before they were used in proliferative
T-cell assays. About 90% of the total protein in these
preparations consisted of fusion proteins, as determined by
SDS-PAGE and Western blot analysis.
(iv) F peptides. Peptides were assembled with an auto-
mated multiple peptide synthesizer equipped with a 48-col-
umn reaction block (AMS 422; ABIMED Analysen-Technik
GmbH, Langenfeld, Germany) and Noa-fluorenylmethoxy-
carbonyl (Fmoc)-protected (1, 10) amino acids (Novabio-
chem, Laufelfingen, Switzerland) as previously described
(58). All peptides were prepared with acetylated N termini
and C-terminal carboxamides. The peptides were depro-
tected and cleaved from the solid support (58) with trifluo-
roacetic acid in the presence of scavengers (as described in
reference 1 but with a slight modification, i.e., water re-
placed the recommended phenol). The crude peptides (puri-
ty of 50 to 90% for 18-meric peptides and >85% for 12-meric
peptides, as determined by reverse-phase high-performance
liquid chromatography analysis) were used in immunological
experiments in concentrations of 10-9 to 10-5 M.
T-cell clones. The MV-specific human T-cell clones de-
scribed in this article were established from peripheral blood
mononuclear cells (PBMC) of three healthy adult individuals
(donors 3, 4, and 5) and of two children (donors 1 and 2).
PBMC were obtained from the children 4 weeks after clinical
symptoms of measles were observed. All T-cell clones were
generated from PBMC that were stimulated and cloned with
autologous MV-infected B-LCL and were cultured in vitro
as previously described (52, 53; some of the T-cell clones
previously described have been renamed, and information
regarding this redesignation can be obtained from corre-
sponding author). Briefly, the T-cell clones were maintained
in culture in 96-well round-bottomed microtiter plates
(Greiner Labor Technik, Nurtingen, Germany) in 150 ,ul of
RPMI 1640 supplemented with 10% (vol/vol) pooled human
AB serum, 2 mM L-glutamine, penicillin (100 U/ml), strep-
tomycin (100 ,ug/ml), 10-5 M 2-mercaptoethanol, and 20 U of
recombinant interleukin-2 (Boehringer, Mannheim, Ger-
many) per ml. Growing clones were expanded and kept at a
donsity of 3 x 104 to 5 x 104 cells per well in the presence of
recombinant interleukin-2 and were restimulated with MV-
infected B-LCL every 10 to 14 days of culture.
Cytotoxicity assays. B-LCL were cultured and maintained
in RPMI 1640 supplemented with 5% (vol/vol) fetal calf
serum, 2 mM L-glutamine, penicillin (100 U/ml), streptomy-
cin (100 ,ug/ml), and 10-5 M 2-mercaptoethanol (referred to
herein as complete medium). Autologous or HLA-matched
B-LCL (106 to 107 cells) were infected for 24 h at 37°C with
MV at a multiplicity of infection of 3.0. Alternatively,
B-LCL were incubated during the CTL assay (4 h) with
synthetic peptides (10 nM to 10 ,uM). T-cell clones were
subsequently incubated with 51Cr-labeled B-LCL at effector
cell-to-target cell ratios ranging from 3 to 6. After 4 h of
incubation at 37°C, supernatants free from cells were col-
lected from individual cultures, and the radioactivity in the
supernatants was counted in a gamma counter. Spontaneous
51Cr release (target cells only) and maximal 5 Cr release
(target cells in 2% Triton X-100) were used as control values
in all assays. Results are expressed as the mean percentage
of specific target cell lysis ± the standard deviation of
triplicate cultures.
Proliferative T-cell assays. Autologous PBMC and HLA-
typed B-LCL were used as stimulator cells for proliferative
responses of T-cell clones. PBMC were incubated for 3 h at
37°C with purified F (3 jig/ml), F-3-galactosidase fusion
proteins (3 ,ug/ml), or synthetic peptides (10 nM to 10 ,uM).
The PBMC were then washed and gamma irradiated (3,000
rads). The B-LCL were incubated with the same antigens
and by the same procedures as described above for the
cytotoxicity assays. In addition, B-LCL were infected with
one of two vaccinia virus recombinants: either a control
vaccinia virus (vv-vsc8) or a vaccinia virus containing the
full-length cDNA encoding MV F (vv-F37). Briefly, 107
B-LCL were infected with vv-vsc8 or vv-F37 at a multiplic-
ity of infection of 5.0 for 16 h at 37°C. After antigen
incubation, the B-LCL were washed and fixed for 15 min
with 0.5% (wt/vol) paraformaldehyde in 1 mM PBS (pH 7.2),
treated for 15 min with 0.2 M glycine in PBS and for 60 min
with complete medium, and then used as stimulator cells.
T-cell clones (3 x 104 cells per well) were subsequently
cultured for 3 days at 37°C in the absence of recombinant
interleukin-2 with B-LCL (2 x 104 cells per well) or PBMC
(105 per well) and pulsed with 0.5 ,uCi of [3H]thymidine over
the last 18 h of culture. The cells were harvested, and the
incorporated radioactivity was counted in a flatbed beta-
scintillation counter (Pharmacia LKB, Uppsala, Sweden).
Results are expressed as the mean counts per minute ±
standard deviation of triplicate cultures.
RESULTS
Generation of F glycoprotein-specific CTL clones. F-spe-
cific T-cell clones were generated in vitro from PBMC of five
individuals by using autologous MV-infected B-LCL as
APC. Although these procedures can yield clones recogniz-
ing different polypeptides of MV (52), all T-cell clones
derived from two donors (3 and 5) and some of the clones
from three other donors (1, 2, and 4) appeared to recognize
F. The present study focused on the identification of the
specificities of six of these F-specific T-cell clones. Among
these clones are four CD4+ T-cell clones (3-F94, 5-F2.1,
4-F76, and 4-F99) derived from three healthy adult individ-
uals and two CD8+ T-cell clones (1-F20 and 2-F40) that were
generated from PBMC obtained from two children 4 weeks
after the onset of clinical symptoms of measles.
All T-cell clones showed an F-specific proliferative T-cell
response to APC that were either pulsed with affinity-
purified F or infected with vaccinia virus expressing F
(vv-F37) (Table 1).
Analyses of the genetic restriction of antigen presentation
revealed that the response of CD4+ T-cell clone 3-F94 is
restricted to HLA-DRw53 of the DR4 or DR7 (Table 1), or
DR9 (data not shown) haplotype; Another HLA-DR deter-
minant (DR2) was required for the antigen-specific T-cell
response of clone 5-F2.1 (Table 1) (52). Clone 4-F99 re-
sponds to F in association with HLA-DQwl, which is
present on DQ5- or DQ6-bearing APC (Table 1). The precise
restriction element for clone 4-F76 could not be determined
with the panel of APC used, although MV-specific T-cell
responses of 4-F76 were inhibited by HLA-DQ-specific
antibodies (52). All T-cell clones appeared to be efficient
cytotoxic effector T lymphocytes in vitro (see references 52
and 54).
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TABLE 1. Genetic restriction and antigen specificity of F protein-specific CTL clonesa
Proliferative T-cell response of T-cell clone of indicated phenotype
APC Antigen HLA shared CD8+ CD4+
1-F20 2-F40 3-F94 4-F76 4-F99 5-F2.1
B-LCL 1 MV Bw62, DR4/w53 43.9 0.1 67.7 0.1 0.1 NT'
B-LCL 2 MV B27, DQ5/wl, DR4/w53 0.1 47.2 33.4 0.2 20.8 NT
B-LCL 3 MV DR4/w53 0.0 0.1 86.2 0.1 0.1 NT
B-LCL 4 MV B27, DQ6/W1, DR2 0.0 49.8 0.1 30.1 19.6 NT
B-LCL 5 MV DQ6/wl, DR2 NT NT NT 0.1 16.8 20.1
B-LCL 6 MV B27, Bw62, DR4/w53 29.6 56.7 47.1 0.2 0.1 NT
B-LCL 7 MV B27, DQ5/wl, DR7/w53 0.1 38.0 72.1 0.1 34.2 NT
Uninfected autologous <0.3 <0.3 <0.3 <0.3 <0.3 <0.3
B-LCL from all
donors
B-LCL W-vsc8 Autologous 0.7 0.5 1.9 NT NT NT
B-LCL W-F37 Autologous 32.8 23.5 27.5 NT NT NT
PBMC -- Autologous NT NT 0.9 0.8 0.7 1.1
PBMC F Autologous NT NT 31.5 43.9 49.9 18.9
a Shown are proliferative T-cell responses of T-cell clones to the following APC: HLA-typed B-LCL, either uninfected or infected for 24 h with MV at a
multiplicity of infection of 3; autologous B-LCL, infected for 18 h with vaccinia virus expressing either control antigen (w-vsc8) or F (w-F37) at a multiplicity
of infection of 5; and autologous PBMC, either untreated (--) or pulsed for 3 h with affinity-purified F at 3 ,ug/ml. Responses are shown as the mean counts per
minute (103) of triplicate cultures (standard deviations are within 10% of the means) (see also references 52 and 54).
b NT, not tested.
Definition of the regions of F recognized by F-specific T-cell
clones. In order to enable the identification of localization of
T-cell epitopes that are recognized by F-specific T-cell
clones, we constructed a set of 3-galactosidase fusion pro-
teins, containing various F amino acid sequences of different
lengths. All HLA class II-restricted F-specific T-cell clones
showed a proliferative T-cell response to the 13-galactosidase
fusion protein containing the major part of F (aa 2 to 513)
(Fig. 1). Proliferative T-cell responses to other 3-galactosi-
dase fusion proteins showed that all clones responded to
different regions of F, i.e., approximately aa 428 to 457 for
clone 3-F94, aa 2 to 231 for the DQ-restricted clone 4-F76,
aa 409 to 428 for clone 4-F99, and aa 358 to 409 for clone
5-F2.1.
Neither purified F nor the F-3-galactosidase fusion pro-
teins can be used to analyze the presentation of F to the
CD8+ T-cell clones 2-F40 and 1-F20, as uptake of these
3-F94 4-F76
exogenous antigens by APC does not result in the generation
of an HILA class I-presentable peptide (reference 54 and data
not shown).
HLA class II-restricted F-specific CTL clones recognize a
cluster of epitopes between aa 379 and 463. Three clones
(5-F2.1, 4-F99, and 3-F94) recognized epitopes of F which
are located between approximately aa 358 and 457. A
number of peptides overlapping this region were synthe-
sized. By simultaneous peptide synthesis, 18-mer peptides of
F with 12-mer sequence overlaps in successive peptides
were synthesized for clone 5-F2.1 and 12-mer sequences
with nonamer overlaps were synthesized for clones 4-F99
and 3-F94. With peptide-pulsed B-LCL or peptide-pulsed
fresh autologous PBMC, proliferative and cytotoxic T-cell
responses could be demonstrated for all T-cell clones. Clone
4-F99, which had a poor response toward peptide-pulsed
B-LCL in a cytotoxic assay, responded well in a prolifera-
4-F99 5-F2.1
MF
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FIG. 1. Regions of F recognized by HLA class II-restricted CTL clones. We measured proliferative T-cell responses of T-cell clones to
autologous PBMC either untreated (--), pulsed for 3 h with 3 ,ug of affinity-purified F (F) per ml, or pulsed for 3 h with 3 jig of 3-galactosidase
fusion proteins, containing different polypeptide sequences of F, per ml.
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amino acid sequence:
370 380 390
.. KSCARTLVSGSFGNRFILSQGNLIANCASILCKCYT..
KSCARTLVSGSFGNRFIL
LVSGSFGNRFILSQGNLI L
GNRFIILSQGNLIANCASI [
SQGNLIANCASILCKCYT I
Measles virus [
0 25 50
% killing
FIG. 2. Peptide specificity of HLA-DR2-restricted T-clone 5-F2.1. The CTL responses (effector cell-to-target cell ratio, 5) to B-LCL
infected with MV and to B-LCL pulsed with four 18-meric peptides (1 ,uM) from a peptide synthesis covering aa 343 to 426 of F are shown.
The underlined sequence shows the overlapping sequence in two successive peptides.
tive T-cell assay in which autologous PBMC were used as
APC.
The epitope of F recognized by clone 5-F2.1 was present
in two successive 18-mers spanning aa 379 to 390 of F (Fig.
2). Clone 4-F99 responded to one of the 12-mer peptides
representing aa 425 to 436, whereas 3-F94 recognized two
successive peptides representing aa 452 to 463 and 455 to
466, respectively (Fig. 3). The F epitope recognized by clone
4-F76 and located near the N terminus of F (approximately
aa 2 to 231 [Fig. 1]) is currently being studied.
Together, these data demonstrate the existence of a clus-
ter of at least three T-cell epitopes located between aa 379
and 466 of F that are recognized by a number of CTL clones
in association with various HLA class II molecules.
F-derived nonamers and decamers are efficiently recognized
amino acid sequence:
by DQwl- and DR4/w53-restricted T-cell clones. Sequence
analysis of peptides eluted from murine and human major
histocompatibility complex class II molecules has revealed
that such peptides range from a 13 to 17 aa in length (16, 45).
Although HLA class II-restricted T cells can be stimulated
by peptides with a relatively short length of 8 to 10 aa, longer
peptides are usually more effective (3). We also found that
relatively short synthetic peptides of F can be presented to
HLA class II-restricted T-cell clones. In the case of clone
3-F94, two peptides containing a sequence of 9 aa were able
to stimulate the clone. These data indicate that relatively
short synthetic peptides of F may be presented to T-cell
clones. The peptides recognized by clones 4-F99 and 3-F94
were therefore minimized in length by constructing a set of
nested peptides, with either C- or N-terminal deletions.
clone 4-F99 clone 3-F94
430 440 450 460
HCPVVEVNGVTIQVGSRRYPDAVYLHRIDLGPPISLERLDVGTNL
HCPVVEVNGVTI n
VVEVNGVTIQVG
VNGVTIQVGSRR
VTIQVGSRRYPD D
QVGSRRYPDAVY D
SRRYPDAVYLHR
YPDAVYLHRIDL D
AVYLHRIDLGPP D
LHRIDLGPPISL
IDLGPPISLERL
GPPISLERLDVG- S
- ISLERLDVGTNL 0
measles virus _ *
not tested
not tested
I
0 20 40 60 0 20 40 60
103cpm % killing
FIG. 3. Peptide specificities of clones 4-F99 and 3-F94. The CTL responses (effector cell-to-target cell ratio, 5) to B-LCL infected with MV
and to B-LCL pulsed with 12-meric peptides (1 ,uM) covering aa 422 to 466 of F are shown. Clone 4-F99 was tested in a proliferative assay
with autologous PBMC pulsed with the same peptides (1 AM) or with UV-irradiated MV (10 ,ug/ml; see reference 52). Boldface sequences
represent peptides that are recognized.
clone 5-F2.1
400
..........................................
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10 cpm
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Peptides:
1) PVVEVNGVTIQVGS
2) VVEVNGVTIQVGS
3) VEVNGVTIQVGS
4) EVNGVTIQVGS °
5) VNGVTIQVGS
6) PVVEVNGVTIQVG
7) PVVEVNGVTIQV
8) PVVEVNGVTIQ
9) PVVEVNGVTI
10) EVNGVTIOV
11) VNGVTIQV
12) EVNGVTIQ
o 10?t
peptides
w? 10
M 0.1pd
0.01
gM peptide
% killing
100
Peptides:
1) LGPPISLERLDVGT
2) GPPISLERLDVGT
3) PPISLERLDVGT
4) PISLERLDVGT 0
5) ISLERLDVGT 1 2A
6) SLERLDVGT 4 5 1
7) LGPPISLERLDVG 7
8) LGPPISLERLDV 9I01
9) PISLERLDVG
10) ISLERLDVG
11) SLERLDVG peptides gM peptide
12) PISLERLDV
13) ISLERLDV
FIG. 4. Minimal lengths of peptides required for the presentation of F to HLA-DQwl-restricted T-cell clone 4-F99 (A) and to
HLA-DR4/w53-restricted CTL clone 3-F94 (B). C- and N-terminally deleted peptides containing the epitopes (x axis) were tested in four
different concentrations (y axis) in a proliferative T-cell assay (A) or in a CTL assay (B) with peptide-pulsed autologous PBMC or B-LCL,
respectively, as APC. The T-cell responses (z axis) are shown; standard deviations are within 10% of the mean counts per minute. exp.,
experiment. Minimal-length peptides recognized are underlined.
Cytotoxic (3-F94) and proliferative (4-F99) T-cell responses
toward the peptides were measured with a range of peptide
concentrations (Fig. 4, experiment 1). Depending on the
outcome of this experiment, a second set of nested peptides
with combined C- and N-terminal deletions were synthe-
sized in order to define the actual minimal sequence of these
peptides that could be presented to these clones (Fig. 4,
experiment 2). From these experiments, it can be concluded
that the minimal peptide sequence efficiently recognized by
clone 4-F99 is the nonapeptide EVNGVTIQV, representing
aa 427 to 435 of F (Fig. 4). The minimal peptide recognized
by clone 3-F94 turned out to be the decamer PISLERLDVG,
representing aa 454 to 463 of F, and this peptide was as
efficiently recognized as the longer ones covering this se-
quence (Fig. 4). Although the amino acid proline at the first
position of the 11-mer PISLERLDVGT can be deleted, the
resulting peptide ISLERLDVGT required at least a 10-fold-
higher peptide concentration to sensitize targets for killing
by the clone. Deletion of this residue in the decamer PISL-
ERLDVG, resulting in peptide ISLERLDVG, abolished the
capacity to be recognized by clone 3-F94 (Fig. 4).
The nonapeptide RRYPDAVYL is recognized by clone
2-F40 and shows considerable homology to other HLA-B27
binding peptides. Among the HLA class I-restricted F-spe-
cific CTL clones that were generated from the PBMC of
children with acute measles, clone 2-F40 recognized an F
epitope presented by HLA-B27 molecules. Amino acid
sequence analyses of endogenous peptides isolated from
HLA-B27 molecules and of viral peptides which bind to
HLA-B27 molecules have revealed a peptide binding motif
for HLA-B27 molecules (20). This motif is characterized by
an arginine found in all such peptides at position 2 and by a
preference for charged amino acids at positions 1 and 9.
Furthermore, hydrophobic and nonpolar or small polar
J. VIROL.
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amino acid sequence: clone 2-F40
430 440 450 460
VNGVTIQVGSRRYPDAVYLHRIDLGPPISLERLDVGTNL
VNGVTIQVGSRR
VTIQVGSRRYPD
QVGSRRYPDAVY
SRRYPDAVYLHR
YPDAVYLHRIDL
AVYLHRIDLGPP
LHRIDLGPPISL
IDLGPPISLERL
GPPISLERLDVG
ISLERLDVGTNL
measles virus
FIG. 5. HLA-B27 restricted CTL-clone 2-F4
nonamer peptide RRYPDAVYL of F (aa 438 t
responses (effector cell-to-target cell ratio, 3) t
with MV, B-LCL pulsed with 12-meric peptid
peptide synthesis covering aa 428 to 466 of F,
peptide RRYPDAVYL representing aa 438 to 44
amino acid residues are often found at pc
respectively (15, 20, 31). These findings
search for an HLA-B27 binding motif in the
only nonamer sequence of F which fulfill
was the sequence consisting of aa 438
DAVYL). Among the sets of peptides us
II-presentable peptides, a 12-mer peptide
sequence (SRRYPDAVYLHR) was actuall
ulate the HLA-B27 restricted CTL clone 2-]
nonamer peptide RRYPDAVYL was subs(
sized, and clone 2-F40 responded to this pep
5). RRYPDAVYL indeed showed considera
other HLA-B27 binding peptides, i.e., a pc
residue at position 1, an arginine at position
amino acid at position 3, and a small hydror
position 6. The other positions of F residue
N
fairly heterogeneous in comparison with other HLA-B27
binding peptides (Fig. 6).
DISCUSSION
Analysis of antigen-specific proliferative and CTL re-
I sponses in healthy adults and in a patient with multiple
sclerosis seropositive for MV showed the presence of class
...I...... II-presentable T-cell determinants on the structural proteins
of MV that are recognized by CD4+ CTL (19, 43, 44). From0 experience with inactivated measles virus vaccines, it hasI become apparent that the F protein is indispensable for the
I induction of long-lasting protective immunity against MV
o (33, 34, 38). In agreement with this, we have previously
o shown that the F protein is an important target protein for
major histocompatibility complex class II-restricted CTL
cloned from MV-seropositive healthy adults with a history of
......measles (52). Recently, Partidos and Steward (42) showed,
- ,I on the basis of a predictive HLA-DR1 binding peptide motif,
0 50 100 that the sequence consisting of 288 to 302 of F contained a
% killing promiscuous T-cell epitope.
.0 responds to the In this article, we show that in addition to the HLA-DR1to 446). The CTL- binding motif in aa 288 to 302, the F protein harbors at least
:o B-LCL infected two class II-presentable peptides in aa 379 to 463 that are
'es (1 ,uM) from a recognized by cloned CD4+ CTL in association with differ-
and the nonamer ent DR alleles. It is clear from Fig. 4 that the truncated
.6 of F are shown. peptide PISLERLDVG is the core sequence that apparently
binds to HLA-DR. Consistent with the tentative DR binding
motifs proposed by several groups (14, 22, 40, 41), this
)sitions 3 and 6, peptide contains hydrophobic residues at positions 2 and 9
prompted us to and a noncharged residue at position 7 (Fig. 6). Further
F sequence. The truncation of the amino terminus reduced the target-sensi-
ed these criteria tizing capacity of the peptide by more than 1,000-fold. This
to 446 (RRYP- strongly argues against the presence of isoleucine instead of
ed to map class proline at position 1. The 12-mer sequence recognized by
containing this clone 5-F2.1 in association with DR2 contains the amino acid
ly found to stim- sequence FILSQGNLI, which fits virtually all of the criteria
F40 (Fig. 5). The for DR binding patterns (Fig. 6): hydrophobic residues at
equently synthe- positions 1, 2, 8, and 9 (14, 22), glutamine at position 5 (22),
tide as well (Fig. and a small residue at position 3 (40). Binding studies with
ible homology to this peptide will be necessary to confirm its expected affinity
)sitively charged for DR2. When examining a large collection of class II
2, a hydrophobic binding determinants, including a DQ-restricted sequence of
phobic residue at Plasmodium falcipanrm gp190 Al (5), Hill et al. (14) ob-
Ds 438 to 446 are served that a large portion could be aligned to give a pattern
HLA-DRw53: P.:..LE..:........
. .. ...
.............
HLA-DQw: E:--:NG VTS I QN VI, ......
....o
.....::a i o c dA Do7. a.: n ~........... s
HLA-D 2 I
..
~~~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
...,.....
...................:::::::::::::::::::::::::::::::::::
S:RYs-WA I R T R (Influenza
... ....3 anchorfregio.................~~~~~~~~..
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FIG. 6. Peptide binding motifs of class I- and class II-presentable peptides of F. NP, nucleoprotein; HIV, human immunodeficiency virus.
Shaded regions are explained in the Discussion.
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of an amino-terminal hydrophobic residue and a small resi-
due at position 6. When the core sequence of the DQwl-
restricted peptide EVNGVTIQV recognized by clone 4-F99
was examined, we observed that it could be aligned to reveal
the same pattern (Fig. 6). Additionally, a hydrophobic resi-
due was found at position 9. Thus the sequence consisting of
aa 379 to 463 of F contains three T-cell epitopes that all have
common features of class II binders: hydrophobic residues
at positions 1 and/or 2 and at position 9.
On the basis of analysis of the T-cell response in MV-
seropositive adults and in a patient with multiple sclerosis, it
has been argued that CTL directed against MV are primarily
CD4+ class II restricted (17, 18), despite earlier analyses of
the T-cell response toward MV which showed evidence for
CD8+ class I-restricted CTL activity against MV (21, 23,
48). Recently we have demonstrated that in recovery from
acute measles, CD8+ class I-restricted CTL are the predom-
inant MV-specific effector cells (53). Moreover, we showed
that CD8+ class I-restricted MV-specific CTL can also be
cloned from healthy MV-seropositive adults (52). One of the
CTL clones, 2-F40 (from a patient with acute measles),
showed an HLA-B27-restricted recognition of F (Fig. 5). A
search based on a known HLA-B27 binding peptide motif
revealed a nonamer sequence in F (aa 438 to 446) consistent
with such a motif (20). This sequence, RRYPDAVYL,
contains an arginine anchor at position 2, another arginine at
position 1, a tyrosine at position 3, and a small hydrophobic
residue on position 6 (Fig. 6). Using the set of 12-mer
peptides with a 3-aa overlap spanning this sequence, we
found that only the peptide containing this entire nonamer
sequence sensitized targets for killing by the CTL clone.
Subsequently, we showed that it was indeed the nonapeptide
that contained the core sequence (Fig. 5).
Collectively, our data show that the sequence consisting
of aa 379 to 463 of F contains a cluster of epitopes recogniz-
able by CD4+ as well as CD8+ CTL in association with
different class II and class I molecules, respectively. Further
analysis of F for the presence of class I binding epitopes in
particular is required, as F or parts of it will be indispensable
components of future inactivated vaccines against measles.
Our recent results showing that F incorporated in immune-
stimulating complexes (ISCOMs) can sensitize targets for
class II- as well as class I-restricted killing by CTL (54),
together with the evidence that ISCOMs containing viral
glycoproteins can induce virus-neutralizing antibodies and
protection (7, 27, 28, 39, 51, 55, 56) and can prime for class
I-restricted CTL (13, 30, 49), indicate the potential of an
ISCOM-based vaccine containing F in addition to other
structural proteins of MV.
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